Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The coprimary objectives of the study are to test whether ixekizumab Q2W/Q4W is superior to FAE and is superior to MTX at Week 24 in the treatment of patients with moderate-to-severe psoriasis who are candidates for systemic therapy as measured by 75% improvement in Psoriasis Area and Severity Index (PASI 75) from baseline assuming, that non-adherent patients are treatment failures.
Critère d'inclusion
- Moderate to Severe Plaque Psoriasis